

肝炎文献リスト_2026年5月号

岡本宏明

2026-05-1

Host species-specific mutations in the thumb domain of the 3D^{pol} polymerase are required for efficient replication of human hepatitis A virus in mice

Misumi I, Shirasaki T, Xie L, Yonish B, Gonzalez-Lopez O, Hirai-Yuki A, Chen X, Li Y, Whitmire J K, Lemon S M

PLoS Pathog 22(5): e1014213, 2026

PMID: 42113844

<https://doi.org/10.1371/journal.ppat.1014213>

ヒト HAV がマウスで効率よく増殖するために必要な 3D^{pol} 領域変異

2026-05-2

Post-translational modifications of NTCP: A regulatory nexus for bile acid transport and HBV entry

Yu F, Zhu Y, Li N, Peng Q, Ye F, Luo Q, Xia J, Hu X

Biomedicines 14(5):978, 2026 <https://doi.org/10.3390/biomedicines14050978>

NTCP の翻訳後修飾: 胆汁酸輸送と HBV 侵入をつなぐ制御機構

2026-05-3

Receptor recognition of hepatitis B and D viruses: Structural insight and its application to drug discovery

Shionoya K, Kobayashi C, Matsuzawa K, Watashi K

Antiviral Res 250:106418, 2026

PMID:42031258

HBV・HDV の受容体認識機構: 構造解析と創薬への応用

2026-05-4

An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma

Batista M N, Bordignon J, Mosimann A L P, Bobrowski T, Chen H A, Tobin-Xet G, Barrall E A, Prokhnevskaya N, Vaidya A B, Lewy T, Dinnon K H, 3rd, Seifert L L, Zeck B, Quirk C, Ho Y J, Filliol A, Wolfisberg R, Jiang C, Cogliati B, Chiriboga L, Theise N, MacDonald M R, Kamphorst A O, Scheel T K H, Sheahan T P, Billerbeck E, Lowe S W, Rosenberg B R, Rice C M

J Hepatol 84(6):1062-76, 2026

PMID:41825745

ウイルス性肝線維化・肝癌を再現した免疫正常マウスモデル

2026-05-5

Generation of HBV cccDNA using single-stranded M13 phage DNA for authentic minichromosome functionality

Li Y, Hua T, Hao M, Chen L, Huang W, Fang Z, Ashuo A, Li Y, Yi Z, Gu H, Yuan Z, Chen J

J Virol e00035-26, May 14 [Epub ahead of print]

PMID: 42132423

<https://doi.org/10.1128/jvi.00035-26>

一本鎖 M13 ファージ DNA を用いた HBV cccDNA 作製法の開発: 本物に近い HBV ミニクロモソームの再現

2026-05-6

Understanding HBV immunopathogenesis to inform future immune-based therapies

Bossis M, Le P H, Asselah T, Baumert T F, Tonnerre P

Antiviral Res 106424, May 4 [Epub ahead of print]

PMID: 42092701

<https://doi.org/10.1016/j.antiviral.2026.106424>

HBV 感染の免疫メカニズム解明と新規免疫療法へ応用

2026-05-7

RANBP3 and RAN orchestrate CRM1-mediated nuclear export of hepatitis B virus RNAs

Wang M, Chen Q, Zheng Y, Yin J, Zhu G, Zhao K, Xu Z, Hua R, Zhou M, Zhang L, Zhao G, Yang S, Amat Z, Xia Y, Cheng X

J Virol e00267-26, Apr 30 [Epub ahead of print]

PMID:42059628

RANBP3 と RAN による HBV RNA 核外輸送機構の解明

2026-05-8

B-BEST: Profiling the intrahepatic HBV reservoir at single-cell resolution ([Editorial] to 90315)

Roca Suarez A A, Testoni B, Zoulim F

Hepatology 001779, Apr 29 [Epub ahead of print]

PMID: 42054399

<https://doi.org/10.1097/hep.0000000000001779>

単一細胞解析で迫る肝内 HBV リザーバーの実態

2026-05-9

Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus

Richter E, Klohn M, Nocke M K, Friedrich M E, Todt D, Steinmann E, Bruggemann Y

JHEP Rep 101885, May 4 [Epub ahead of print]

PMID: 42092617

<https://doi.org/10.1016/j.jhepr.2026.101885>

CRISPR-Cas13 を用いた HEV に対する新規抗ウイルス戦略

2026-05-10

Nicotinamide metabolism is essential for hepatitis C Virus replication and the production of infectious lipo-viro-particles

Toesca J, Castell M, Jacquemin C, Lalande A, Ogire E, Burlaud-Gaillard J, Roingeard P, Ramiere C, Mathieu C, Perrin-Cocon L, Lotteau V, Vidalain P O, Diaz O

PLoS Pathog 22(4): e1014165, 2026

PMID: 42018568

<https://doi.org/10.1371/journal.ppat.1014165>

ニコチンアミド代謝は HCV 増殖および感染性リポウイルス粒子生成に不可欠

2026-05-11

Hepatitis B: A review

Jeng W J, Yip T C, Lok A S

JAMA 2026.6070, May 4 [Epub ahead of print]

PMID:42081318

B 型肝炎診療の総説

2026-05-12

Environmental investigation of a hepatitis A outbreak associated with spring water consumption in an Anabaptist community: Kentucky, 2018-2019

Miko S, Kahler A, Roundtree A, Benedict K, Foster M, Thoroughman D, Odegard A, Khoury J, Rush C, Zafrullah M, Hayden T, Purdy M, Ganova-Raeva L, Williams D, Mounsey L, Massey A, Mattioli M

J Water Health 24(2):264-77, 2026

PMID: 41764395

<https://doi.org/10.2166/wh.2026.248>

湧水飲用に関連した A 型肝炎集団発生の環境調査: ケンタッキー州、2018~2019 年

2026-05-13

Effective inactivation of hepatitis A virus in the edible *Ulva lactuca* seaweed using dielectric barrier discharge (DBD)-plasma treatment

Roy P K, Jeon E B, Roy A, Park S Y

Food Sci Technol Int 10820132251412041,

Jan 5 [Epub ahead of print]

PMID:41490208

食用海藻アオサにおける HAV の不活化: プラズマ処理の有効性

2026-05-14

Molecular detection and characterization of hepatitis E virus in wild boars (*Sus scrofa*) from northern Italy

Olivieri E, Rigamonti S, Montagna R, Lodola C M, Ricchi M, Vicari N, Prati P

Res Vet Sci 208:106259, 2026

PMID:42119550

北イタリアのイノシシにおける HEV の分子疫学

2026-05-15

ONWARD: A one health, pan-European multidisciplinary network advancing surveillance, research, clinical management and control of zoonotic hepeviruses

Rivero-Juarez A, Velebit B, Johne R, Abravanel F, Reuter G, Dudman S, Kamar N, Jemersic L, di Bartolo I, Hasanoglu I, Anita A, Cook N, Ruta S, Nauwelaers I, Milojević L, Todorovska E, Mojsova S, Zerja A, Avellon A, der Honing R H, Harvala H, Nascimento M S J, Mesquita J R

J Clin Virol 184:105944, 2026

PMID: 42001595

<https://doi.org/10.1016/j.jcv.2026.105944>

HEV 対策の最前線: 多分野連携による欧州ネットワークの取り組み

2026-05-16

Elevated soluble LAG-3 in chronic hepatitis B and T-cell responses to checkpoint blockade

Chen J, Zu Y, Jiang G, Fang Z, Yuan Z

Antiviral Res 250:106419, 2026

PMID:42025968

慢性 B 型肝炎における可溶性 LAG-3 上昇とチェックポイント阻害時の T 細胞応答

2026-05-17

Updated hepatitis D seroprevalence among HBsAg-positive persons aged ≥ 6 years in the United States, National Health and Nutrition Examination Survey, 2007–2018

Casillas S M, Chida A, Drobeniuc J, Sandul A L, Kamili S, Jiles R B, Thomas D L, Tobian A A R, Patel E U, Teshale E H

Clin Infect Dis ciag274, Apr 25 [Epub ahead of print] PMID:42033144

米国における HBs 抗原陽性者の HDV 抗体保有率の最新動向(2007~2018 年)

2026-05-18

Clinical profile and prognostic predictors in hepatitis A virus-induced acute liver failure
Kumar K, Shaileshbhai Shah H, Mehta N N, Kumar Jain A, Kumar Mahala V, Anand Saraswat V

J Clin Exp Hepatol 16(3):103471, 2026 PMID:41778216

A 型肝炎による急性肝不全の臨床像と予後予測因子

2026-05-19

Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico

Bautista-Mondragon C A, Mijangos-Trejo A M, Gonzalez-Chon O, Mondragon-Ratkovich P, Chavez-Tapia N C

World J Gastrointest Surg 18(1):112767, 2026 PMID: 41695881

<https://doi.org/10.4240/wjgs.v18.i1.112767>

A 型肝炎患者における死亡・肝移植リスク因子: メキシコ症例集積

2026-05-20

Hepatitis C distribution across diverse population groups in the Eastern Mediterranean Region: An umbrella review

Abdolahinia Z, Eybpoosh S, Jangipour Afshar P, Karamoozian A, Azadmanesh K, Sharifi H

PLoS One 21(4): e0346782, 2026 PMID: 42013172

<https://doi.org/10.1371/journal.pone.0346782>

東地中海地域における C 型肝炎の分布: 多様な集団を横断したレビュー

2026-05-21

Direct antiviral agents may obviate the need for liver transplantation for HCV cirrhosis by the end of the decade

Haynes N, Cochran A, Baimas-George M, Archie W, Mylarapu N, Casingal V, Soto J, Zamor P, Delemos A S, Schmeltzer P A, Zacks S, Adlakha N, Denny R, Russo M L, Eskind L, Vrochides D

Surgeries 7(2):51, 2026 <https://doi.org/10.3390/surgeries7020051>

DAA 薬の登場で HCV 肝硬変の移植は不要になる?

2026-05-22

Novel HBx-interacting host cellular factors regulate dynamic nuclear and cytoplasmic localization of hepatitis B virus X protein (HBx)

Ariumi Y

Virology 110931, May 2 [Epub ahead of print]

新規 HBx 結合宿主因子が制御する HBx タンパクの核内および細胞質内局在動態

2026-05-23

Investigating an outbreak of hepatitis A in an urban area of Madurai, Tamil Nadu, 2023

Subramanian V, Palaniappan K, Ramalingam S, Abdulkader R S

Indian J Public Health 70(Suppl 1):S85-7, 2026

PMID: 41629245

https://doi.org/10.4103/ijph.ijph_649_25

インド都市部での A 型肝炎アウトブレイク調査(2023 年)

2026-05-24

Copper-enhanced electrochemical immunosensor based on gold nanoparticles for the quality control of hepatitis A virus vaccines

Dorozhko E V, Solomonenko A N, Erkovich A V, Koltsova A V, Korotkova E I, Kolobova E N, Semin V O, Nikulin L G, Mikhailova T V, Kazachinskaya E I, Saqib M

Talanta 297(Pt A):128579, 2026

PMID:40669328

金ナノ粒子・銅増強型電気化学免疫センサーによる HAV ワクチン品質評価

2026-05-25

Non-invasive diagnostic biomarkers of viral hepatitis based on multi-omics technology: Recent advances and challenges

Liu X Y, Lu J F, Wang Z Y, Zheng S S

Hepatobiliary Pancreat Dis Int 25(1):15-22, 2026

PMID:41219025

マルチオミクス技術が拓くウイルス性肝炎の非侵襲的診断

2026-05-26

Long-term antibody persistence after hepatitis A vaccination in healthy toddlers: Insights from modeling

Espul C, Cuello H H, Saravia A, Vargas M E, Bravo C, Augard C, Coudeville L

Infect Dis Ther 15(2):527-38, 2026

PMID: 41385061

<https://doi.org/10.1007/s40121-025-01278-0>

幼児期の A 型肝炎ワクチン接種後の抗体持続: モデル解析からの知見

2026-05-27

Autoimmune hepatitis unmasked by acute viral hepatitis: A diagnostic and therapeutic challenge

Rose S, Ashraf M U, Mitra S, Rani L, De A, Verma N, Premkumar M, Taneja S, Duseja A

J Clin Exp Hepatol 16(3):103497, 2026

PMID:41852657

急性ウイルス性肝炎を契機に顕在化した自己免疫性肝炎

2026-05-28

Combined HDV RNA and anti-HDV measurement for the management of HBV/HDV coinfection

Ricco G, Cavallone D, Colombatto P, Coco B, Oliveri F, Damone F, Petralli G, Romagnoli V, Salvati A, Surace L, Cali A, Vianello B, Bonino F, Brunetto M R

Hepatology 001776, May 1 [Epub ahead of print] PMID: 42065872

[HBV/HDV 重複感染管理における HDV RNA と HDV 抗体の同時測定の有効性](#)

2026-05-29

Toward a functional cure for chronic hepatitis B: Current landscape and future directions in Japan

Handa Y, Lee E Y, Tanaka Y

Hepatol Res 70179, Apr 30 [Epub ahead of print] PMID: 42057710

<https://doi.org/10.1111/hepr.70179>

[慢性 B 型肝炎の機能的治癒を目指して: 日本における現状と将来展望](#)

2026-05-30

HBV-induced miR-4461 downregulation correlates with elevated fibrinogen alpha chain expression in hepatocellular carcinoma

Kanai M, Sakai A, Date T, Aoki Y, Mihara F, Kokudo T, Inagaki F, Takemura N, Kokudo N, Sugiyama M

J Gastroenterol 026-02433-1, Apr 30 [Epub ahead of print] PMID: 42062626

<https://doi.org/10.1007/s00535-026-02433-1>

[肝細胞癌における HBV 関連 miR-4461 低下とフィブリノーゲン \$\alpha\$ 鎖発現亢進の関連](#)

2026-05-31

Lipid nanoparticle-encapsulated PolyI:C as an adjuvant enhances both humoral and cellular immune responses to the hepatitis B vaccine

Zhao Z, Wang B, Wang H, Zhang Q, Liang Y, Liu Y

Vaccines 14(5):397, 2026 <https://doi.org/10.3390/vaccines14050397>

[脂質ナノ粒子封入ポリ I:C は B 型肝炎ワクチンの液性・細胞性免疫を増強する](#)

2026-05-32

The value of hepatitis E screening sensitivity: Lookback investigation in German blood donors

Plumers R, Dreier J, Mandl A, Knabbe C, Vollmer T

Viruses 18(5):507, 2026 <https://doi.org/10.3390/v18050507>

[ドイツの献血者調査から見た HEV スクリーニング感度の重要性](#)

2026-05-33

Rare but real: Unusual manifestations of hepatitis A

Bansal S, Mahajan A, Mantan M

Trop Doct 56(1):128-30, 2026

PMID:41148216

[稀だが見逃せない: A 型肝炎の非典型的な症状](#)

2026-05-34

Host factors DDB2 and DNA polymerase delta are linked to cccDNA persistence in hepatitis B virus and occult hepatitis B virus-related hepatocellular carcinoma

Singsung K, Vorasittha A, Tangkijvanich P, Tanaka Y, Chuaypen N, Sirichindakul P

J Viral Hepat 33(6): e70182, 2026

PMID:42083260

宿主因子 DDB2 と DNA ポリメラーゼδは、HBV における cccDNA の持続と OBI 関連肝細胞癌に関与する

2026-05-35

Superior efficacy of tenofovir alafenamide compared with entecavir in reducing hepatitis B surface antigen: A multicentre propensity score-matched study using linear mixed-effects models

Kumada T, Atsukawa M, Itokawa N, Arai T, Toyoda H, Tsubota A, Watanabe T, Chuma M, Matsuura K, Hiraoka A, Tada T, Takaguchi K, Kato K, Abe H, Tani J, Ishikawa T, Ogawa C, Asano T, Oikawa T, Matsumoto Y, Akita T, Tanaka J

Aliment Pharmacol Ther 70704, May 4 [Epub ahead of print] PMID:42076967

TAF は ETV より HBs 抗原低下効果に優れる: 多施設共同傾向スコア解析

2026-05-36

Hepatitis E virus and renal injury: A review of pathogenesis, pathology, and clinical management

Shen J, Zhang S

Infect Med 100259, Apr 30 [Epub ahead of print]

<https://doi.org/10.1016/j.imj.2026.100259>

HEV と腎障害: 病因・病理・診療のレビュー

2026-05-37

Chronic HDV infection shows higher HBsAg isoform levels than HBV infection, paralleling HDV replicative activity

D'Anna S, Piermatteo L, Magnapera A, Grossi I, Tramontozzi C, Olivero A, Duca L, Torre G, Teti E, Di Lorenzo A, Malagnino V, Iannetta M, Grelli S, Paba P, Bertoli A, Ceccherini-Silberstein F, Baiocchi L, Francioso S, Lenci I, Milella M, Saracino A, Ciancio A, Brancaccio G, Sarmati L, Lampertico P, Rizzetto M, Caviglia G P, Salpini R, Svicher V

Viruses 18(5):515, 2026

<https://doi.org/10.3390/v18050515>

慢性 HDV 感染では HBV 単独感染よりも HBs 抗原アイソフォームが高値を示す: HDV 増殖活性と相関

2026-05-38

Detection and genomic characterization of a bat Orthohepadnavirus in urban areas of Brazil: Implications for zoonotic surveillance

Conselheiro J A, Reis-Menezes A A

Zoonotic Diseases 6(2):15, 2026

<https://doi.org/10.3390/zoonoticdis6020015>

ブラジル都市部コウモリ由来 HBV 類縁ウイルスの発見が示す人獣共通感染症監視の重要性

2026-05-39

Long-term persistence of hepatitis A virus immunity in healthcare workers upto 25 years after vaccination

Noviello C, Arico M, Scazzi F L, Riformato G, Florio O, Furio A, Larocca A M V, Palmieri C, Manzi S, Cantalice M A, Tafuri S, Stefanizzi P

J Viral Hepat 33(6): e70187, 2026

PMID: 42124375

<https://doi.org/10.1111/jvh.70187>

A型肝炎ワクチン免疫は25年持続するか:医療従事者での検討

2026-05-40

CD72 downregulation is associated with increased CD5⁺ B cell proliferation and IL-10 production via ERK/Syk signaling in chronic HBV infection-associated liver disease

Li B, Zhao L, Zhu Q, Xie S

Virus Res 199744, May 8 [Epub ahead of print]

PMID: 42107788

<https://doi.org/10.1016/j.virusres.2026.199744>

慢性HBV感染肝疾患におけるCD72低下とCD5陽性B細胞活性化の関連

2026-05-41

How wastewater monitoring is helping to investigate a hepatitis A outbreak linked to oysters' consumption

Le Guyader F S, Figoni J, Ollivier J, Chaghouri A, Parnaudeau S, Nisavanh A, Le Menec C, Normand J, Deslandes A, Martel M, Erouart S, Roque-Afonso A M

Food Environ Virol 18(2):21, 2026

PMID: 42126500

<https://doi.org/10.1007/s12560-026-09694-2>

下水モニタリングが解明に役立ったカキ関連A型肝炎アウトブレイク(フランス)

2026-05-42

Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis

Cao M, Wei F, Georges D, Alberts C J, Clifford G M, de Martel C

Gut 2025-337838, May 14 [Epub ahead of print]

PMID: 42135055

<https://doi.org/10.1136/gutjnl-2025-337838>

肝細胞癌は何が原因か?:世界・地域・国別にみた最新メタ解析

2026-05-43

Diabetes, male sex, low levels of HBsAg, HDV RNA and ALT predict spontaneous HDV suppression in chronic hepatitis D

Kamal H, Jargalsaikhan G, Enkhtaivan S, Lindahl K, Dashtseren B, Lkhagva-Ochir O, Ulziibadrakh T, Bungert A, Degasperi E, Lampertico P, Wedemeyer H, Dashdorj N B, Aleman S

Hepatology 001786, May 12 [Epub ahead of print]

PMID: 42118989

<https://doi.org/10.1097/hep.0000000000001786>

糖尿病・男性・HBsAg/HDV RNA/ALT低値は慢性D型肝炎におけるHDV自然抑制の予測因子

2026-05-44

Molecular insights into the mechanisms of occult hepatitis B virus infection

Mahdavi S, Abyazi M A, Gouvarchin Ghaleh H E, Golmohammadi R, Salimi Jeda A
Arch Virol 171(6):176, 2026 PMID:42096075

[Occult HBV 感染の成立機序を分子レベルで読み解く](#)

2026-05-45

Field performance and acceptability of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) for detecting high viral load among pregnant women in The Gambia (PROTECT-B)

Famiglietti A M, Drammeh S, Vo-Quang E, Dibba B, Jammeh K, Jallow A E, Touray A B, Keita S, Gaye Y, Manneh B, Sallah Y, Badjie S, Boyer S, Perieres L, Petitfour L, Khan S, Guingane A N, Tiendrebeogo A, Kania D, D'Alessandro U, Tanaka Y, Lemoine M, Ndow G, Shimakawa Y

Clin Infect Dis ciag311, May 12 [Epub ahead of print] PMID:42119150

[ガンビア妊婦での HBV 母子感染対策に向けた HBcrAg 迅速検査の性能評価](#)

2026-05-46

Hepatitis B control in jeopardy

Karakasidis E, Mazin R

Eur J Clin Microbiol Infect Dis 026-05542-0,

May 12 [Epub ahead of print] PMID: 42115488

<https://doi.org/10.1007/s10096-026-05542-0>

[危機に直面する B 型肝炎対策](#)

2026-05-47

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection in the high-replicative low-inflammatory phase: A 48-week randomized controlled trial

Luo Q, Xu R, Zhang Y, Xu W, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L

J Med Virol 98(5): e70960, 2026

PMID: 42095461

<https://doi.org/10.1002/jmv.70960>

[高ウイルス量・低炎症期慢性 B 型肝炎に対する TAF 治療のランダム化比較試験](#)

2026-05-48

Effectiveness, safety and patient-reported outcomes of bulevirtide therapy in chronic hepatitis delta: Real-world evidence from a prospective observational study

Mengato D, Battistella S, Cadore A, Giunco E M, Zanaga P, Zappitelli T, Romano A, Tonon M, Pasin F, Barbaro F, Sasset L, Scribano L, Gambato M, Berti G, Simioni P, Cattelan A, Burra P, Venturini F, Russo F P

J Viral Hepat 33(6): e70181, 2026

PMID:42108541

[慢性 D 型肝炎におけるブレビルチド治療の実臨床成績](#)

2026-05-49

Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment

Goyal A, Cotler S J, Matthews G V, Page K, Kushner T, Etzion O, Martinello M, Dahari H
J Infect Dis 2026; 333(5): e1260, May 9 [Epub ahead of print] PMID:42103311

[HCV RNA 早期陰性化例における DAA 短期療法の可能性:数理モデルによる検討](#)

2026-05-50

Hepatitis C virus and Type 2 diabetes: Mechanisms, clinical impact, and post-DAA management

Chang S S, Liu C H, Chan S Y, Lin L T
J Med Virol 98(5): e70952, 2026

PMID: 42101220

<https://doi.org/10.1002/jmv.70952>

[HCV と 2 型糖尿病:メカニズムから DAA 治療後フォローまで](#)

2026-05-51

A comparative study of entecavir and tenofovir alafenamide on quantitative HBsAg reduction in patients with CHB

Lee J, Jin Y J

J Med Virol 98(5): e70958, 2026

PMID:42101128

[慢性 B 型肝炎患者における HBs 抗原量減少効果:ETV と TAF の比較試験](#)

2026-05-52

Evaluating viral pollution in wastewater and mediterranean ecosystems

Puchades-Colera P, Giron-Guzman I, Cuevas-Ferrando E, Diaz-Reolid A, Falco I, Aznar R, Farre M, Llorca M, Perez-Cataluna A, Sanchez G

Food Environ Virol 18(2):20, 2026

PMID: 42053963

<https://doi.org/10.1007/s12560-026-09693-3>

[廃水および地中海生態系におけるウイルス汚染の実態評価](#)

2026-05-53

Clinical course and outcomes of paediatric chronic hepatitis B: Insights from a multicenter longitudinal cohort of 248 patients

Privato R, Pinon M, Buccella V, Corpino M, Giorgio A D, Carrera S, Rubino C, Mandato C, Castellazzi M L, Trapani S, Nicastro E, Indolfi G

J Viral Hepat 33(6): e70183, 2026

PMID:42116670

[小児慢性 B 型肝炎の長期経過と転帰:248 例多施設コホート研究](#)

2026-05-54

Risk of intrahepatic and extrahepatic cancers in hepatitis C virus infection: A nationwide cohort study in Korea, 2005-2023

Park Y, Kim B W, Oh J K, Kim B H, Park S J, Kim K A, Ki M

Liver Int 46(6): e70664, 2026

PMID:42084000

[C 型肝炎患者における肝内・肝外癌のリスク:韓国全国コホート研究](#)

2026-05-55

LINC01012 drives hepatitis B-related hepatocellular carcinoma progression through HNRNPL-mediated stabilization of serine/threonine-protein kinase-S

Zhu J, Dai P

J Med Virol 98(5): e70947, 2026

PMID:42080810

[LINC01012\(long noncoding RNA の一種\)が促進する HBV 関連肝癌進展の新機序](#)

2026-05-56

Hepatitis B challenge dose in vaccinated healthcare personnel susceptible at hire

Vande Hey J M, Ward D, Buys A, Caldera F, Hayney M S

Vaccine 82:128589, 2026

PMID:42000147

[医療従事者における HBV 暴露リスクとワクチン防御](#)

2026-05-57

Advancements in therapeutic HBV vaccines: navigating the path toward functional cure

Wang X, Wu T

Vaccine 82:128610, 2026

PMID:42019132

[HBV 機能的治癒を目指すワクチン治療の最前線](#)

2026-05-58

Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024

Laperche S, de la Taille V, Gallian P, Pouchol E, Humbrecht C, Montembault A, Malard L, Bacquet C, Asso-Bonnet M, Le Cam S, Peyrard T, Tiberghien P

Vox Sang 121(5):581-6, 2026

PMID: 41702688

<https://doi.org//10.1111/vox.70199>

[フランスにおける病原体低減血小板導入後の輸血感染リスク\(2017~2024 年\)](#)

2026-05-59

A unified histopathological framework of liver fibrogenesis in chronic viral hepatitis B, C and coinfection

Dumitrache A, Ionescu N A, Soare L C, Ponepal M C, Tantu A C, Tantu M M, Banita I M, Pisoschi C G

Diseases 14(5):165, 2026

<https://doi.org/10.3390/diseases14050165>

[慢性 B 型/C 型肝炎および重複感染に共通する肝線維化の病理像](#)

2026-05-60

HBV envelope protein-bearing vesicles show preferential uptake in hepatocyte-derived cells

Takayama E, Enomoto M, Nagae M, Tomoda M, Miyazumi Y, Iwaisako Y, Shirasawa R, Suzuki Y, Nakano T, Ueda K, Fujimuro M

Int J Mol Sci 27(10):4331, 2026

<https://doi.org/10.3390/ijms27104331>

[HBV エンベロープ蛋白を持つ小胞は肝細胞に選択的に取り込まれる](#)

2026-05-61

Hepatitis B virus in Gabonese non-human primate: Potential zoonotic circulation and long-term strain persistence

Koumba Mavoungou D S, Boundenga L, Lekana-Douki S E, Pendy N M L, Moukouama S E K, Kombila L B, Falque G, Mangombi J B, Mouinga-Ondeme A, Dedkov V, Dacheux L, Aghokeng A F, N' dilimabaka N

Pathogens 15(5):528, 2026 <https://doi.org/10.3390/pathogens15050528>

ガボンの霊長類に持続する HBV 株とその人獣共通感染リスク

2026-05-62

Identification of cyclin L1 as a host factor regulating hepatitis B virus replication

Owino C O, Narmada B C, Yi Lin G, Aw P P K, Ganesh N, Siying J T, Plissonnier M-L, Matan T T, Shirgaonkar N, Bifani P, Levrero M, Periyasamy G, Gee Lim S, DasGupta R
Viruses 18(5):545, 2026 <https://doi.org/10.3390/v18050545>

HBV 複製を制御する宿主因子サイクリン L1 の同定

2026-05-63

Hepatitis E seroprevalence in pregnancy

Singh M, Goel A, Verma M L, Mehrotra S, Sankhwar P L

Indian J Gastroenterol 45(2):250-8, 2026

PMID:41706413

妊婦における HEV 抗体保有率の実態(インド)

2026-05-64

CROI 2026: Advances in epidemiology and treatment of viral hepatitis

Gunaratne S H

Top Antivir Med 34(2):481-5, 2026

PMID: 42127258

<https://www.iasusa.org/wp-content/uploads/2026/04/34-2-481.pdf>

カンファレンス「CROI 2026」にみるウイルス性肝炎研究の最新動向

2026-05-65

Hepatitis E virus-associated neurological injury and neurotropic cellular mechanisms

Guo Z, Tian Y, Cheng M, Yin W, Sun Y, Ou Y, Peng X, Liu T, She R, Hu Y, Tian J

Front Cell Infect Microbiol 16:1810452, 2026

PMID: 42100653

<https://doi.org/10.3389/fcimb.2026.1810452>

HEV 関連神経障害および神経向性細胞メカニズム

2026-05-66

Long-term outcomes of patients with hepatitis C virus-related liver transplantation in a high-volume transplant center

Ataman E, Harputluoglu M, Bilgic Y, Gozukara H G, Aladag M, Ince V, Yilmaz S

BMC Gastroenterol 026-04678-9,

Apr 29 [Epub ahead of print]

PMID: 42056875

<https://doi.org/10.1186/s12876-026-04678-9>

大規模移植センターにおける HCV 関連肝移植の長期成績(トルコ)

2026-05-67

Neonatal inflammatory profiles associated with perinatally acquired hepatitis C viral infection

Fisher S A, Sandoval G J, Saade G R, Hughes B L, Reddy U M, Chien E K, Tita A T N, Thorp J M, Jr., Metz T D, Sabharwal V, Simhan H N, Swamy G K, Heyborne K D, Sibai B M, Yee L M, El-Sayed Y Y, Casey B M, Parry S, Prasad M

Pediatr Infect Dis J 005262, May 5 [Epub ahead of print] PMID:42083082

[周産期 HCV 感染児に特徴的な新生児炎症プロファイル](#)

2026-05-68

Identification and functional analysis of key miRNAs and target genes associated with failure of HBV mother-to-child transmission prevention

He Q, Zou X, Zheng C, Zhang J, Li J, Hu L, Zeng T, Huang Z, Zeng P, Wei J, Cui H, Su Y, Li H

PLoS One 21(5): e0348899, 2026 PMID: 42096447

<https://doi.org/10.1371/journal.pone.0348899>

[HBV 母子感染予防失敗に関連する miRNA および標的遺伝子の同定と機能解析](#)

2026-05-69

Liver stiffness by non-invasive tests predicts hepatocellular carcinoma and liver-related complications following viral eradication with direct-acting antivirals in chronic hepatitis C: a retrospective cohort study

Ananchuensook P, Treeprasertsuk S, Komolmit P, Thanapirom K

BMC Gastroenterol 026-04920-4,

May 14 [Epub ahead of print]

PMID: 42135704

<https://doi.org/10.1186/s12876-026-04920-4>

[非侵襲的肝硬度測定でみる DAA 治療後の肝癌リスク](#)

2026-05-70

Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study

Qiu X, Yin Y, Zhang S, Liu W

BMC Gastroenterol 026-04830-5,

May 9 [Epub ahead of print]

PMID: 42106615

<https://doi.org/10.1186/s12876-026-04830-5>

[低ウイルス量慢性 B 型肝炎に対する新規テノホビル製剤\(TMf\)の有効性と安全性](#)

2026-05-71

Uncovering core stemness biomarkers in HBV-HCC through integrated multi-omics

Xu H, Li H, Hu L, Wang X

PLoS One 21(5): e0349171, 2026

PMID: 42133686

<https://doi.org/10.1371/journal.pone.0349171>

[マルチオミクスで探る HBV 関連肝細胞癌の”幹細胞性”バイオマーカー](#)

2026-05-72

Niemann-Pick C1 maintains cholesterol homeostasis in late endosomes to drive hepatitis B virus endosomal escape

He S, Zhang W, Wang C, Li R, Xu K, Feng B, Cheng S, Tao N, Yu H, Li Z, Chen J, Ren J
Antiviral Res 251:106437, 2026 PMID: 42140524

<https://doi.org/10.1016/j.antiviral.2026.106437>

コレステロール輸送分子のニーマン・ピック C1 は、HBV のエンドソームから細胞質への脱出を促進する

2026-05-73

Twenty-year trends in liver transplantation among hepatitis D virus-infected patients in the U.S. and Europe

Younossi Z M, Germani G, Buti M, Papatheoriditis G, Lampertico P, Adam R, Wong R J, Nader F, Karam V, Henry L, Alqahtani S, Stepanova M, Burra P
Clin Gastroenterol Hepatol 2026.04.028,

May 12 [Epub ahead of print] PMID:42128039

米国・欧州における HDV 感染患者の肝移植の 20 年推移

2026-05-74

Association of hepatitis A virus with periodontitis: a cross-sectional and genetic analysis
Zheng Z, Wu J

Eur J Clin Microbiol Infect Dis 026-05531-3,

May 16 [Epub ahead of print] PMID:42142249

HAV と歯周病の関連: 横断研究と遺伝学的解析

2026-05-75

First detection of hepatitis E virus in wastewater in Costa Rica

Mendoza-Guido B, Calvo T, Chacon L, Pisano M B, Masachessi G, Chacon L

Food Environ Virol 18(2):23, 2026

PMID:42159919

コスタリカの下水から初めて HEV を検出

2026-05-76

Evolving strategies in HBV management: Insights from updated international guidelines

Enomoto M, Wong G L, Huang R, Nguyen M H

Hepatol Res 70205, May 17 [Epub ahead of print]

PMID:42144940

最新国際ガイドラインに学ぶ B 型肝炎診療の新戦略

2026-05-77

Serum markers of fibroinflammatory activity PRO-C3 and CPa9-HNE are associated with liver-related outcomes in patients with chronic hepatitis C

Skovgaard E T, Wiggers T, Karsdal M, Goetze J P, Leeming D J, Patel K

J Infect Dis 233(5):831-9, 2026

PMID:41169194

血清線維化・炎症マーカー (PRO-C3 と CPa9-HNE) は慢性 C 型肝炎の肝関連予後因子である

2026-05-78

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares

Wedemeyer H, Gane E, Agarwal K, Fehmi Tabak O, Fornis X, Akarca U S, Morozov V, Aleman S, Buti M, Yilmaz G, Lampertico P, Jezorwski J, Kakuda T N, Bakala A, Pehlivanov N, Verbinnen T, Lenz O, Biermer M

J Hepatol 2026.05.007, May 15 [Epub ahead of print] PMID:42142631

siRNA 製剤 JNJ-73763989 は D 型肝炎患者の HBsAg と HDV RNA を低下させるが ALT 上昇に注意

2026-05-79

Efficacy and safety of 12-week coblopassvir/sofosbuvir regimen for hepatitis C in Northwest China: A multi-center prospective study

Yan L, Wubuliashan M, Kou X, Tuerxun M, Yang M, Ji F, He Y, Wang J, Zhu L, Gao X, Jing F, Ding X, Du H, Zhang Y, Jiang H

J Med Virol 98(5): e70978, 2026 PMID: 42159424

<https://doi.org/10.1002/jmv.70978>

中国北西部における C 型肝炎への 12 週間コブロパスビル/ソホスブビル療法の有効性と安全性

2026-05-80

Prognostic value of apolipoprotein A-I in acute hepatitis E virus (HEV) infection: A single-center, retrospective, cohort study from Shanghai, China

Jiang X, Huang H, Chen L, Fang Q, Xiang X, Cai W, Xie Q, Wang X

J Med Virol 98(5): e70986, 2026 PMID:42175869

急性 E 型肝炎におけるアポリポ蛋白 A-I の予後予測能

2026-05-81

Metabolic factor-based machine learning model for mortality prediction in acute hepatitis E: Development and validation from a dual-center cohort

Fu H, Song S, Xiao Y, Du B, Zhao G, Zhou T, Du Y

Dig Liver Dis 58(5):660-9, 2026 PMID: 41723028

<https://doi.org/10.1016/j.dld.2026.02.002>

代謝因子に基づく機械学習モデルによる急性 E 型肝炎死亡予測

2026-05-82

Long-term immunity and IgG subclass response following hepatitis E vaccination: A longitudinal cohort study in Matlab, Bangladesh

Haque W, Islam S, Dudman S, Overbo J, Dembinski J L, Stene-Johansen K, Julin C H, Bhuiyan M T R, Goswami D R, Bhuiyan E S, Parvin N, Hasan M K, Binte Aziz A, Rahman M, Qadri F, Clemens J D, Zaman K

Int J Infect Dis 166:108505, 2026 PMID: 41763639

<https://doi.org/10.1016/j.ijid.2026.108505>

E 型肝炎ワクチン接種後の長期免疫と IgG サブクラス応答(バングラデシュ)

2026-05-83

Diagnostic performance of molecular and serological markers for hepatitis E virus and *Toxoplasma gondii* coinfection across gestation in HIV-positive pregnant women

Asaga P M, Bulus D, Makpo J, Yako A, Airiohuodion P E

J Infect Public Health 19(5):103214, 2026

PMID: 41932266

<https://doi.org/10.1016/j.jiph.2026.103214>

HIV 陽性妊婦における HEV・トキソプラズマ重複感染診断の精度評価

2026-05-84

Hepatitis B, C, and E viruses in solid organ transplantation: donor and recipient perspectives

Khan J, Kozuch J, Aslam S

JHLT Open 12:100533, 2026

PMID: 42005560

<https://doi.org/10.1016/j.jhlto.2026.100533>

固形臓器移植における HBV、HCV、HEV: ドナーとレシピエントの視点から

2026-05-85

Acute pancreatitis as an extrahepatic complication of acute hepatitis E infection: A case report

Shah S A R, Alam I, Noman Ali Shah S, Cheema U, Akilimali A

Clin Case Rep 14(5): e72658, 2026

PMID: 42093709

<https://doi.org/10.1002/ccr3.72658>

急性 E 型肝炎の肝外合併症としての急性膵炎の 1 例

2026-05-86

Global burden and time trends of vaccine-preventable diseases in children and adolescents

Jin X, Wang R, Tu S, Yuan C, Ge F, Liu Y, Wang S, Ma Y, Sun G

Ital J Pediatr 026-02256-z, May 5 [Epub ahead of print]

PMID: 42087201

<https://doi.org/10.1186/s13052-026-02256-z>

小児・若年者におけるワクチン予防可能疾患の世界的負担とその推移

2026-05-87

Evaluation of the analytical performance of the MAGLUMI HEV IgM and IgG assays for automated detection of HEV antibodies and comparison with the microplate Wantai assay

Geng D, Zhu Y, Zhang H, Liu K, Chen S, Fang Z, Zhang Z

Virolog J 026-03187-1, May 8 [Epub ahead of print]

PMID: 42104377

<https://doi.org/10.1186/s12985-026-03187-1>

自動化 MAGLUMI HEV IgM/IgG 測定系と Wantai 法(マイクロプレート)との比較

2026-05-88

Acute hepatitis E virus infection in adults, Cayenne, French Guiana, 2015-2022

de Colnet C, Aboikoni A, Nacher M, Epelboin L, Michaud C, Barbry A, Izopet J, Le Turnier P

Infect Dis Now 55(5):105087, 2025

PMID: 40349922

<https://doi.org/10.1016/j.idnow.2025.105087>

仏領ギアナにおける成人急性 HEV 感染の実態(2015～2022 年)